Relapsed/Refractory Solid Tumors research hub

I3Y-MC-JPCS: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors and Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients with Relapsed/Refractory Neuroblastoma (Part C).

This study is testing a new medicine, abemaciclib, combined with other treatments for children and young adults with solid cancers that have come back or not responded to previous treatment. Researchers want to find the safest and most effective dose.